Telomir Pharmaceuticals, Inc. (TELO) Análisis de acciones

Descripción de la empresa

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage biotechnology firm dedicated to the research and development of small-molecule therapeutics aimed at addressing the upstream biological drivers of aging and associated age-related pathologies. Within the broader healthcare sector, the company functions specifically within the biotechnology industry, a field characterized by high research intensity and significant regulatory hurdles prior to commercialization. The enterprise currently holds a market capitalization of $45.38M, while its annual revenue and employee count are not disclosed in the available financial data. This market valuation places the company in the micro-cap category, indicating a smaller scale operation that is highly sensitive to clinical trial outcomes and funding milestones rather than established commercial sales streams.

Salud financiera

The company reports negative net income of $-10,413,205 for the trailing twelve months, whereas revenue and EBITDA figures are not available for disclosure. The substantial negative net income relative to the unreported revenue suggests a cost structure dominated by research and development expenses typical of preclinical entities that have not yet achieved commercial revenue generation. Free cash flow stands at $-86,566, which indicates that the company is consuming cash reserves to fund its operational activities and scientific development efforts. The gross margin, operating margin, and profit margin are all recorded at 0.0%, reflecting the pre-revenue status where no sales have occurred to generate traditional profitability metrics. On the liability side, the firm holds $7.29M in cash against $473,752 in debt, resulting in a debt-to-equity ratio of 8.01, which technically denotes a leveraged balance sheet structure given the high ratio, though the absolute debt level is minimal. The current ratio is 5.14, signaling robust short-term liquidity as the company possesses ample current assets to cover its immediate obligations despite the negative earnings. Return on equity is -317.6% and return on assets is -152.0%, metrics that reveal that management is currently destroying shareholder value through aggressive investment in preclinical research rather than generating returns on deployed capital.

Evaluación de valoración

The trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is listed at -4.71, a metric that implies the market is pricing in a future path to profitability or continuing losses depending on the forward earnings estimate used. The price-to-book ratio stands at 7.67, indicating that the market values the company's equity at a significant premium relative to its net asset book value, likely reflecting the potential value of its intellectual property and pipeline assets. Price-to-sales and EV/EBITDA metrics are not available for citation given the lack of revenue and EBITDA data in the financial records. Over the past year, the stock has traded between a 52-week high of $3.23 and a 52-week low of $1.05. Without a specific current share price provided in the facts to calculate the exact percentage, the trading range demonstrates high volatility with a potential swing of over 200% from the low to the high. The beta value is -0.73, a negative coefficient that suggests the stock price moves inversely to the broader market or possesses unique volatility characteristics that do not correlate positively with general market indices.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are not available in the provided financial data, preventing a direct comparison of earnings expansion versus revenue expansion. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that the firm retains all earnings and cash flow to reinvest into its preclinical drug development programs. This reinvestment strategy is typical for biotechnology companies at the preclinical stage, where capital is directed toward advancing Telomir-1 through regulatory pathways rather than distributing income to shareholders. Consequently, the overall growth and income profile is defined entirely by capital appreciation potential derived from clinical milestones rather than dividend income or organic revenue growth from existing products.